 |
Faculty |
 |
Statement of Need |
 |
Activity Goal |
 |
Learning Objectives |
 |
Financial Support |
 |
Target Audience |
 |
Credit Information |
Addressing Barriers to Care: Strategies for the Management of Patients with Schizophrenia
neuroscienceCME Live and On Demand
Premiere Date: Wednesday, December 16, 2009Click here to access additional resources mentioned in the live broadcast.
This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, December 16, 2010
Note: Credit Is No Longer Available
 | John W. Newcomer, MD (Moderator) Senior Associate Dean for Clinical Research Leonard M. Miller Professor of Psychiatry and Behavioral Sciences Leonard M. Miller School of Medicine University of Miami Miami, FL |
 | Henry A. Nasrallah, MD The Sydney W. Souers Endowed Chair University of Cincinnati College of Medicine Professor and Chairman, Department of Neurology and Psychiatry Saint Louis University School of Medicine St. Louis, MO |
 | Dawn I. Velligan, PhD Professor and Co-Director Division of Schizophrenia and Related Disorders Department of Psychiatry The University of Texas Health Science Center at San Antonio San Antonio, TX |
| Andrew W. Goddard, MD (Content/Peer Reviewer) Professor of Psychiatry Indiana University School of Medicine Director, Adult Psychiatry Outpatient Clinic and Study Center Indiana University Hospital Bloomington, IN |
Until the past decade, there was generally a pessimistic attitude about the treatment of patients with schizophrenia and their outcomes. One key concept that has been identified as critical in optimizing the care and outcomes of patients is continuity of care by a team of healthcare providers. Continuity of care is widely viewed as a key quality indicator for outpatient mental health care and is essential to prevention of relapse and re-hospitalization.(1)
Yet, progress has lagged in the implementation and measurement of continuity of care in clinical practice. In a recent educational activity by CME Outfitters, over 220 psychiatrists responded that their main reason for not changing practice immediately regarding continuity of care was they did not know where to start, demonstrating a gap in knowledge and performance regarding the implementation of this process in clinical practice. A first step to improving care is identifying the barriers that exist. Patient barriers, physician barriers and system barriers can be significant obstacles requiring education of the entire mental healthcare team in order to begin to break down the walls and allow clinicians to provide the best care for each patient.
The identification of the barriers can be the first step in empowering both the provider and the patient. This can highlight to psychiatrists, other healthcare providers, payors, and healthcare systems what barriers may exist and how they are impacting the outcomes and lives of patients.
In this neuroscienceCME Live and On Demand activity, faculty will highlight barriers to optimal care and their impact on the outcomes and lives of patients with schizophrenia and propose practical strategies and tools that can be utilized to improve the care of patients with schizophrenia.
- Adair CE, McDougall GM, Beckie A, et al. History and measurement of continuity of care in mental health services and evidence of its role in outcomes. Psychiatr Serv 2003;54:1351-1356.
To offer clinicians optimal strategies to more effectively manage individuals with schizophrenia across the continuum of care.
At the end of this CE activity, participants should be able to:
- Assess key barriers in practice that impact continuity of care in the management of patients with schizophrenia.
- Implement treatment plans in concordance with patients that focus on improving continuity of care.
- Incorporate tools and measures in practice to improve discharge transitions of patients with schizophrenia.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify key barriers in practice that impact continuity of care in the management of patients with schizophrenia.
- Discuss treatment plans in concordance with patients that focus on improving continuity of care.
- Identify tools and measures in practice to improve discharge transitions of patients with schizophrenia.
This CME/CE-certified activity is supported by an educational grant from Janssen, Division of Ortho- McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals interested in the management of patients with schizophrenia.
CME Credit (Physicians):
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Indiana University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
This continuing nursing education activity was approved by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned approval code 7ZDR4H-10. 1.0 contact
hours will be awarded upon successful completion.
CEP Credit (Psychologists):
CME Outfitters is approved by the American Psychological Association to sponsor continuing education for psychologists. CME Outfitters maintains responsibility for this program and its content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited
by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education.
1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-999-09-027-L01-P (live presentation)
376-999-09-027-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations can be
completed online at www.neuroscienceCME.com (click on the
Testing/Certification link under the Activities tab—requires free
account activation), and participants can print their certificate
or statement of credit immediately (70% pass rate required).
Otherwise, participants should fully complete and return both
the credit request form and activity evaluation located within the
course guide for this activity. A certificate or statement of credit
will be mailed within 4–6 weeks to all who successfully complete
these requirements. This website supports all browsers except
Internet Explorer for Mac. For complete technical requirements
and privacy policy, visit www.neuroscienceCME.com/technical.asp.
This continuing education activity is jointly sponsored by Indiana University School of Medicine, CME LLC, and CME Outfitters, LLC.
Disclosure Declaration
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM), CME LLC, and CME Outfitters, LLC, (CMEO) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in activities sponsored by IUSM, CME LLC, and CMEO are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Note: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
Dr. Newcomer has disclosed that he receives grant support from The National Institute of Mental Health, The National Alliance for Research on Schizophrenia and Depression, Bristol-Myers Squibb Company, Janssen, L.P.; Pfizer Inc., and Wyeth Pharmaceuticals. He serves as a consultant to AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, litigation regarding medication effects, GlaxoSmithKline, H. Lundbeck A/S, Janssen, L.P., Organon Pharmaceuticals USA Inc., Otsuka America Pharmaceutical, Inc., Pfizer Inc., Solvay Pharmaceuticals, Inc., Tikvah Therapeutics, Inc., VANDA Pharmaceuticals, and Wyeth Pharmaceuticals. He serves on the data safety monitoring committee of Dainippon Sumitomo Pharma America, Inc., Organon Pharmaceuticals USA Inc., Schering-Plough Corporation, and Vivus, Inc. Dr. Newcomer also receives product development royalties for Metabolic Screening forms from Compact Clinicals/Jones and Bartlett Publishing.
Dr. Nasrallah has disclosed that he receives grant support from AstraZeneca Pharmaceuticals LP, Janssen, L.P., the National Institute of Mental Health, Otsuka America Pharmaceutical, Inc., Roche, and Sanofi-aventis. He serves as a consultant to Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Dainippon Sumitomo Pharma, Janssen, L.P., Pfizer Inc., Schering-Plough Corporation, and Vanda Pharmaceuticals. He serves on the advisory boards of Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Janssen, L.P., Pfizer Inc., and Vanda Pharmaceuticals. He is on the speakers bureaus of AstraZeneca Pharmaceuticals LP, Janssen, L.P., and Pfizer Inc.
Dr. Velligan has disclosed that she receives grant support from AstraZeneca Pharmaceuticals LP, Janssen L.P., and Pfizer Inc. She serves as a consultant to Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Janssen L.P., and Pfizer Inc.
Dr. Goddard has disclosed that he receives grant support from AstraZeneca Pharmaceuticals LP and Janssen, L.P. He serves as a consultant to Bristol-Myers Squibb Company and Pfizer Inc.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Indiana University School of Medicine, CME LLC, CME Outfitters, LLC, the faculty, and Ortho-McNeil Janssen Scientific Affairs, LLC, do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-065-121609-01
